Swiss drug manufacturers Novartis have developed a drug for advanced lung cancer. European health regulators have recommended approval of the drug, which is intended to treat patients with a specific genetic mutation. A new class medicines Zykadia, or ceritinib known as ALK (Anaplastic lymphoma kinase) inhibitors was approved last year in the United States. It is designed for use in non-small cell lung cancer patients who have previously been treated ...
Read More
You have just read an article categorized health
titled Novartis Develops New Drug for Advanced Lung Cancer.
Written by:
editor -
Saturday, February 28, 2015
There are currently no comments for "Novartis Develops New Drug for Advanced Lung Cancer"
Post a Comment